Metformin

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placeb

Effect: decline; HR 1.09; CI: 95% CI 1.021, 1.173

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94

Higher baseline adiponectin was associated with lower incident diabetes risk in the metformin group, persisting after full adjustment for baseline and 1-year changes in diabetes risk factors and after

Effect: improvement; HR 0.79; CI: 95% CI 0.66, 0.94